‘Major step forward’: TGA approves first pharmacological therapy for OSA

5 minute read


The dual GLP-1/GIP receptor agonist tirzepatide can now be used to treat the condition in some patients. See who is eligible.


This content is for AHPRA registered professionals only.
Join Now

End of content

No more pages to load

Log In Register ×